PharmaBoardroom

The South Korean medical devices market has expanded significantly in recent years; from USD 4.2 billion in 2013 to USD 5.5 billion in 2017.…

Shingyu Bae, CEO of MDimune, explains how the company’s new exosome drug delivery system increases efficacy and reduces toxicity compared with other…

Dae Jung Kim, president of Daiichi Sankyo Korea provides an insight into the rationale behind the company’s focus on the cardiovascular therapeutic…

Kyung Kook Lee, chairman of KMDIA, explains the association’s role in working with the medical devices industry to boost both the local market and…

Jung Hyun Yun lifts the lid on Biosolution’s new stem cell technology that could revolutionize the treatment of cartilage-related ailments, such as…

Antimicrobial resistance (AMR) is a global health concern that we are increasingly understanding the consequences of and pulling together to try and…

Paul Henry Huibers, president of Lilly Korea discusses Lilly’s strong double-digit growth following a challenging period of restructuring. Huibers…

The South Korean government has designated the promotion of artificial intelligence (AI)-based drug development and healthcare innovation as a…

Uloff Münster, general manager of Merck Biopharma Korea provides his insights into the Korean healthcare system. Dr Münster also discusses the drug…

Young Jack Lee, CEO of LSK Global PS, Korea’s largest local contract research organization (CRO) gives his insights on the evolution of the clinical…

Yong-Ik Kim, president of Korea’s National Health Insurance Service (NHIS), provides an insight into the implementation of the upcoming MoonCare…

Kyungjin Peter Kim, CEO of ST Pharm, provides an insight into his expansion of the company’s operations from simply a CMO into a CDMO and new drug…